Daxor Corporation ( DXR) Stock. Should you Buy or Sell? $ 12.80
-0.06 (-0.47 %)
Daxor Corporation AnalysisUpdated on 10-09-2022
|Volume Avg.||$2.71 thousand|
|Market Cap||$51.75 M|
|52 Week Range||$9.52 - $14.55|
Daxor Corporation opened the day at $12.80 which is -0.47 % on yesterday's close. Daxor Corporation has a 52 week high of $14.55 and 52 week low of $9.52, which is a difference of $5.03. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $51.75 M and total net profit is $5821183 which means the company is trading at 8.89 times profit to market capitalization. Theoretically, if you were to buy Daxor Corporation for $51.75 M, it would take 15 years to get your money back. Daxor Corporation are in the Medical Instruments & Supplies space which will have a sweet spot and industry standard for net profit multiples.
Daxor Corporation Stock Forecast - Is Daxor Corporation a Buy or Sell?
|DCF Score||Strong Buy|
|ROE Score||Strong Sell|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-6.122|
Valuing Daxor Corporation
|Price Book Value Ratio||2.354||Price To Book Ratio||2.354|
|Price To Sales Ratio||71.179||Price Earnings Ratio||-11.626|
How liquid is Daxor Corporation
|Debt Ratio||0.153||Debt Equity Ratio||0.181|
|Long Term Debt To Capitalization||0.125||Total Debt To Capitalization||0.000|
Latest news about Daxor Corporation
Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.
Daxor Corporation (NASDAQ:DXR ) Q2 2022 Earnings Conference Call August 25, 2022 4:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh - CEO & President Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Edward Wu - Ascendiant Capital Michael Samuels - Berthel Fisher Operator Good afternoon, and welcome to the Daxor Corporation First Half 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode.
Conference Call to be held on the same day at 4:30 p.m. Eastern Time
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.
About Daxor Corporation
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.